BB&T Investment Services Inc. decreased its holdings in shares of Sanofi SA (NYSE:SNY) by 15.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,308 shares of the company’s stock after selling 2,268 shares during the quarter. BB&T Investment Services Inc.’s holdings in Sanofi were worth $535,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of SNY. Bank of Nova Scotia Trust Co. bought a new position in shares of Sanofi during the third quarter valued at approximately $125,000. Bronfman E.L. Rothschild L.P. grew its stake in shares of Sanofi by 46.0% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock worth $186,000 after acquiring an additional 1,362 shares during the last quarter. SeaCrest Wealth Management LLC purchased a new stake in shares of Sanofi in the fourth quarter worth $200,000. Synovus Financial Corp purchased a new stake in shares of Sanofi in the fourth quarter worth $224,000. Finally, BLB&B Advisors LLC grew its stake in shares of Sanofi by 36.8% in the fourth quarter. BLB&B Advisors LLC now owns 5,573 shares of the company’s stock worth $240,000 after acquiring an additional 1,500 shares during the last quarter. 8.98% of the stock is owned by institutional investors.
A number of research analysts have weighed in on the company. Sanford C. Bernstein reissued a “market perform” rating and issued a $45.00 target price (down previously from $50.00) on shares of Sanofi in a report on Thursday, February 8th. ValuEngine downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research cut Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. TheStreet cut Sanofi from a “b-” rating to a “c+” rating in a report on Tuesday, February 13th. Finally, Liberum Capital upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Friday, March 23rd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $49.33.
Sanofi stock traded up $0.17 during trading hours on Thursday, hitting $40.93. 585,342 shares of the stock traded hands, compared to its average volume of 1,832,782. Sanofi SA has a 1 year low of $38.14 and a 1 year high of $50.65. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.26 and a current ratio of 1.70. The company has a market cap of $103,383.38, a PE ratio of 13.08, a PEG ratio of 2.08 and a beta of 0.85.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.07). Sanofi had a return on equity of 24.30% and a net margin of 23.25%. The business had revenue of $8.69 billion during the quarter, compared to analyst estimates of $8.65 billion. During the same period in the previous year, the company posted $1.25 EPS. The business’s revenue for the quarter was down 2.1% compared to the same quarter last year. analysts predict that Sanofi SA will post 3.36 EPS for the current fiscal year.
The company also recently announced an annual dividend, which will be paid on Monday, June 4th. Shareholders of record on Thursday, May 10th will be issued a dividend of $1.8609 per share. The ex-dividend date of this dividend is Wednesday, May 9th. This represents a dividend yield of 4.72%. This is a boost from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio is presently 35.14%.
TRADEMARK VIOLATION NOTICE: “BB&T Investment Services Inc. Lowers Position in Sanofi SA (SNY)” was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://macondaily.com/2018/04/12/bbt-investment-services-inc-has-535000-position-in-sanofi-sa-sny-updated-updated-updated.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.